Translating monotherapy trials into clinical practice: A look into the abyss

Santiago Arroyo, Emilio Perucca

Research output: Contribution to journalArticle

Abstract

To be approved for monotherapy by regulatory authorities, new antiepileptic drugs (AEDs) must first be tested in well-controlled studies in refractory patients (conversion to monotherapy trials) or in patients with newly diagnosed epilepsy. However, the applicability of the information obtained in these trials to day-to-day clinical practice is limited. Clinical trials in newly diagnosed patients, particularly those allowing dose flexibility, offer more useful information, but a close scrutiny of methodological details is required to avoid misinterpretation of the findings. In many instances, the neurologist has a drug with a label, but lacks critical information on optimal titration rates, optimal target and maintenance dosages, response rates in populations with different epilepsy syndromes, different age ranges and comorbidities, and long-term safety data. Such information becomes available only through general clinical experience, well-designed phase IV studies, and postmarketing surveillance.

Original languageEnglish
Pages (from-to)457-463
Number of pages7
JournalEpilepsy and Behavior
Volume4
Issue number5
DOIs
Publication statusPublished - Oct 2003

Fingerprint

Clinical Trials
Epilepsy
Anticonvulsants
Comorbidity
Maintenance
Safety
Pharmaceutical Preparations
Population
Neurologists

Keywords

  • Anticonvulsants
  • Antiepileptic drugs
  • Clinical trials
  • Monotherapy
  • Polytherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology

Cite this

Translating monotherapy trials into clinical practice : A look into the abyss. / Arroyo, Santiago; Perucca, Emilio.

In: Epilepsy and Behavior, Vol. 4, No. 5, 10.2003, p. 457-463.

Research output: Contribution to journalArticle

@article{612b7893f6094019afcb71ac0b5c28bb,
title = "Translating monotherapy trials into clinical practice: A look into the abyss",
abstract = "To be approved for monotherapy by regulatory authorities, new antiepileptic drugs (AEDs) must first be tested in well-controlled studies in refractory patients (conversion to monotherapy trials) or in patients with newly diagnosed epilepsy. However, the applicability of the information obtained in these trials to day-to-day clinical practice is limited. Clinical trials in newly diagnosed patients, particularly those allowing dose flexibility, offer more useful information, but a close scrutiny of methodological details is required to avoid misinterpretation of the findings. In many instances, the neurologist has a drug with a label, but lacks critical information on optimal titration rates, optimal target and maintenance dosages, response rates in populations with different epilepsy syndromes, different age ranges and comorbidities, and long-term safety data. Such information becomes available only through general clinical experience, well-designed phase IV studies, and postmarketing surveillance.",
keywords = "Anticonvulsants, Antiepileptic drugs, Clinical trials, Monotherapy, Polytherapy",
author = "Santiago Arroyo and Emilio Perucca",
year = "2003",
month = "10",
doi = "10.1016/j.yebeh.2003.07.011",
language = "English",
volume = "4",
pages = "457--463",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Translating monotherapy trials into clinical practice

T2 - A look into the abyss

AU - Arroyo, Santiago

AU - Perucca, Emilio

PY - 2003/10

Y1 - 2003/10

N2 - To be approved for monotherapy by regulatory authorities, new antiepileptic drugs (AEDs) must first be tested in well-controlled studies in refractory patients (conversion to monotherapy trials) or in patients with newly diagnosed epilepsy. However, the applicability of the information obtained in these trials to day-to-day clinical practice is limited. Clinical trials in newly diagnosed patients, particularly those allowing dose flexibility, offer more useful information, but a close scrutiny of methodological details is required to avoid misinterpretation of the findings. In many instances, the neurologist has a drug with a label, but lacks critical information on optimal titration rates, optimal target and maintenance dosages, response rates in populations with different epilepsy syndromes, different age ranges and comorbidities, and long-term safety data. Such information becomes available only through general clinical experience, well-designed phase IV studies, and postmarketing surveillance.

AB - To be approved for monotherapy by regulatory authorities, new antiepileptic drugs (AEDs) must first be tested in well-controlled studies in refractory patients (conversion to monotherapy trials) or in patients with newly diagnosed epilepsy. However, the applicability of the information obtained in these trials to day-to-day clinical practice is limited. Clinical trials in newly diagnosed patients, particularly those allowing dose flexibility, offer more useful information, but a close scrutiny of methodological details is required to avoid misinterpretation of the findings. In many instances, the neurologist has a drug with a label, but lacks critical information on optimal titration rates, optimal target and maintenance dosages, response rates in populations with different epilepsy syndromes, different age ranges and comorbidities, and long-term safety data. Such information becomes available only through general clinical experience, well-designed phase IV studies, and postmarketing surveillance.

KW - Anticonvulsants

KW - Antiepileptic drugs

KW - Clinical trials

KW - Monotherapy

KW - Polytherapy

UR - http://www.scopus.com/inward/record.url?scp=0242522185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242522185&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2003.07.011

DO - 10.1016/j.yebeh.2003.07.011

M3 - Article

C2 - 14527485

AN - SCOPUS:0242522185

VL - 4

SP - 457

EP - 463

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 5

ER -